Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a fixed-dose combination preparation containing three active ingredients: fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is used as a maintenance treatment medication for chronic obstructive pulmonary disease (COPD) and asthma.
Precautions for Using Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Important Limitations
Not indicated for the relief of acute bronchospasm.
Not indicated for status asthmaticus or other acute exacerbations of COPD or asthma that require intensive treatment.
Not indicated for pediatric patients aged 17 years and younger.
Absolute Contraindications
Status asthmaticus or acute exacerbations of COPD or asthma that require intensive treatment.
Patients with a severe allergic reaction to milk proteins.
Patients with a known allergy to fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, or any of the excipients.
Concomitant use with ergotamine-containing, ergot-type medications, or other 5-HT₁ receptor agonists.
Drug Interactions
Potent CYP3A4 inhibitors: Caution is required when used concomitantly with potent CYP3A4 inhibitors such as ketoconazole, as this may cause systemic corticosteroid effects and cardiovascular effects.
Monoamine oxidase (MAO) inhibitors and tricyclic antidepressants: May enhance the cardiovascular effects of vilanterol.
Beta-blockers: May block the bronchodilator effect of beta-agonists and induce severe bronchospasm.
Medication Monitoring for Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)
Cardiovascular Event Monitoring
Vilanterol may cause clinically significant cardiovascular effects, manifested as increased heart rate, elevated blood pressure, and potentially arrhythmias.
Pulmonary Infection Monitoring
May lead to oropharyngeal candidiasis (thrush); regular monitoring is required.
Pneumonia Risk Monitoring
The incidence of pneumonia may increase in COPD patients using this medication; close monitoring for pneumonia-related symptoms is necessary.
Adrenal Function Monitoring
Adrenal insufficiency may occur when switching from systemic corticosteroids to Trelegy Ellipta.
Bone Mineral Density Monitoring
Long-term use of products containing inhaled corticosteroids (ICS) may lead to decreased bone mineral density. It is recommended to assess bone mineral density before starting treatment and conduct regular re-evaluations.
Patient Medication Guidance and Monitoring
COPD maintenance treatment: Inhale one dose of Trelegy Ellipta (100/62.5/25 mcg) once daily.
Asthma maintenance treatment: Inhale one dose of Trelegy Ellipta (either 100/62.5/25 mcg or 200/62.5/25 mcg) once daily.
Immediately rinse the mouth with clean water after each inhalation and do not swallow the rinse water—this helps reduce the risk of oropharyngeal candidiasis.
The medication should be used at a relatively fixed time each day, and no more than one dose should be taken within 24 hours.
